Gastrointestinal Cancer News

The FDA cleared an investigational new drug application for FT536, a chimeric antigen receptor natural killer cell therapy designed to treat adults with certain relapsed or refractory solid tumors.

The FDA granted regenerative medicine advanced therapy designation to CT041, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.

The concept of patients continuing to exercise while undergoing active cancer treatment is not new, but it may need reinforcing.

Increased incidence of early-onset colorectal cancer and precancerous polyp diagnoses among patients at a younger age supported the recommendation for CRC screening at age 45 for all average risk individuals, according to a study.

When some patients with cancer may have limited life expectancies, taking time off as an oncologist can be all the more complicated.

Among patients with large serrated polyps, the risk for bleeding after endoscopic mucosal resection was low, with no significant benefit seen with resection clipping, according to a study.

Younger and older patients with metastatic colorectal cancer had similar survival outcomes despite differences in fitness levels and treatment intensity, according to study results published in Journal of the National Cancer Institute.

National Comprehensive Cancer Network has issued updated guidance on COVID-19 vaccination and pre-exposure prophylaxis for patients with cancer.

The FDA granted fast track designation to LioCyx-M004, a T-cell receptor T-cell therapy for treatment of adults with hepatitis B virus-related hepatocellular carcinoma.

Christopher Li, MD, PhD, has been named the first associate director of diversity, equity and inclusion for the Fred Hutch/University of Washington Cancer Consortium.